Clinical Trials
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Com...
July 19, 2023 | News
9MW2921 is a next generation antibody-drug conjugate (ADC) developed by Mabwell based on IDDC™ (Interchain-Disulfide Drug Conjugate) platef...
July 19, 2023 | News
- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop...
July 18, 2023 | News
XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...
July 17, 2023 | News
Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single cell technologies, announced today the availability of its new CELLSEARCH CTC...
July 14, 2023 | News
This first in-human clinical trial using Velico's spray drying system is taking place at Hoxworth Blood Center, Cincinnati, Ohio; Versiti Blood Center...
July 13, 2023 | News
Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the launch of state-of-the-art flow cytometry clinical trial serv...
July 12, 2023 | News
The multi-center clinical randomized controlled trial on the ''treatment of Chronic Obstructive Pulmonary Disease (''COPD'') by targeted lung denervation a...
July 11, 2023 | News
RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, announce...
July 10, 2023 | News
80Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug ...
July 10, 2023 | News
To initiate TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy for the first-line treatment ...
July 10, 2023 | News
The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...
July 10, 2023 | News
Under the agreement, Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under Current Good Manufacturing Practice (CGMP) regulations to ...
July 06, 2023 | News
RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chi...
July 05, 2023 | News
Most Read
Bio Jobs
News
Editor Picks